Guggenheim sees GeneDx with ‘sticky leadership position,’ starts at Buy

As previously reported, Guggenheim initiated coverage of GeneDx (WGS) with a Buy rating and $88 price target The company has established “an increasingly sticky leadership position” in the rare disease genetic testing market as strong execution and an increasingly differentiated and proprietary database for rare diseases positions the company to drive continued double-digit revenue growth while becoming increasingly profitable, the analyst tells investors.